Hyderabad, 17th November 2025: Teijin Limited and BioVaram (UR Advanced Therapeutics Pvt. Ltd.), a rapidly growing biotech company incubated at ASPIRE, University of Hyderabad, have entered into a strategic alliance to jointly explore opportunities for expanding Teijin’s portfolio of implantable medical devices and regenerative medicine products in India, while introducing BioVaram’s innovative biotech solutions to Japan. By combining the strengths of Japan’s advanced healthcare ecosystem with India’s dynamic innovation environment nurtured at ASPIRE-BioNEST, this collaboration aims to accelerate next-generation therapeutic advancements across both nations.
Under the agreement, the companies will work toward obtaining regulatory approvals and commercializing Teijin’s cardiovascular repair patch, SYNFOLIUMⓇ, in India, while also expanding the reach of regenerative medicine products from Japan Tissue Engineering Co., Ltd. (J-TEC)—a Teijin Group company—across the Indian market. Simultaneously, Teijin will support development and commercialization in Japan of BioVaram’s pipeline, including exosome-based diagnostics and therapeutics, extracellular matrix (ECM) mimics, and bio-derived materials such as Type I atelocollagen. This bilateral exchange marks a significant step toward fostering cross-border innovation in regenerative healthcare.
Dr. Takayuki Nakano, Mission Executive and General Manager, Regenerative Medicine & Implantable Medical Device Division, Teijin Limited, stated that the partnership is a major milestone in Teijin’s global expansion strategy, uniting complementary strengths to address unmet medical needs in Japan and India. Dr. Jaganmohan Reddy, Founder and CEO of UR Advanced Therapeutics, emphasized that the collaboration accelerates BioVaram’s mission to bring India’s next-generation biotech innovations to global markets through deep research, cutting-edge technologies, and scalable manufacturing.
Founded in 2020 at the University of Hyderabad’s ASPIRE-BioNEST, BioVaram is supported by the ASPIRE Seed Fund, BIRAC BIG Grant, and investors including Bhavya Constructions and Dr. K. I. Varaprasad Reddy of Shantha Biotechnics. Recognized among the “Top 5 Startups” at BioAsia 2024, BioVaram develops AI-designed peptides, exosomes, and bio-derived materials for regenerative medicine. Mentored by Dr. Varaprasad Reddy, the company remains committed to building affordable and transformative biotech solutions.
Established in 1918, Teijin Limited (TSE: 3401) is a global technology-driven conglomerate with core businesses in high-performance materials and healthcare. With more than 170 companies and 20,000 employees worldwide, Teijin recorded consolidated revenues of JPY 1,005.5 billion in FY2025. As part of its long-term growth strategy, the Teijin Group aims to achieve JPY 20 billion in regenerative medicine sales by 2030 through global partnerships like this one.
Together, Teijin and BioVaram will assess business feasibility, regulatory pathways, and product integration strategies to advance regenerative medicine and expand access to breakthrough healthcare solutions in both countries.